ATE374623T1 - Förderer der nervenregeneration die als aktiven bestandteil einen semaphorinhemmer enthalten - Google Patents

Förderer der nervenregeneration die als aktiven bestandteil einen semaphorinhemmer enthalten

Info

Publication number
ATE374623T1
ATE374623T1 AT01954366T AT01954366T ATE374623T1 AT E374623 T1 ATE374623 T1 AT E374623T1 AT 01954366 T AT01954366 T AT 01954366T AT 01954366 T AT01954366 T AT 01954366T AT E374623 T1 ATE374623 T1 AT E374623T1
Authority
AT
Austria
Prior art keywords
semaphorin
inhibitor
nerve
active ingredient
nerve regeneration
Prior art date
Application number
AT01954366T
Other languages
English (en)
Inventor
Toru Kimura
Kaoru Kikuchi
Kazuo Kumagai
Norio Hosotani
Akiyoshi Kishino
Original Assignee
Dainippon Sumitomo Pharma Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dainippon Sumitomo Pharma Co filed Critical Dainippon Sumitomo Pharma Co
Application granted granted Critical
Publication of ATE374623T1 publication Critical patent/ATE374623T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
    • C07D311/82—Xanthenes
    • C07D311/84—Xanthenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 9
    • C07D311/86—Oxygen atoms, e.g. xanthones

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Fodder In General (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT01954366T 2000-07-28 2001-07-27 Förderer der nervenregeneration die als aktiven bestandteil einen semaphorinhemmer enthalten ATE374623T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000228555 2000-07-28
JP2000390985 2000-12-22

Publications (1)

Publication Number Publication Date
ATE374623T1 true ATE374623T1 (de) 2007-10-15

Family

ID=26596897

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01954366T ATE374623T1 (de) 2000-07-28 2001-07-27 Förderer der nervenregeneration die als aktiven bestandteil einen semaphorinhemmer enthalten

Country Status (8)

Country Link
US (2) US7244761B2 (de)
EP (1) EP1306093B1 (de)
JP (1) JP4975231B2 (de)
AT (1) ATE374623T1 (de)
AU (1) AU2001276694A1 (de)
DE (1) DE60130769T2 (de)
ES (1) ES2294014T3 (de)
WO (1) WO2002009756A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0211888A (pt) 2001-08-13 2004-08-24 Univ Florida Res Foudantion In Materiais e métodos para promoção de reparo de tecido nervoso
WO2003062440A1 (en) * 2002-01-21 2003-07-31 Sumitomo Pharmaceuticals Co., Ltd. Xanthone derivative
EP1475382B1 (de) * 2002-01-24 2008-12-10 Dainippon Sumitomo Pharma Co., Ltd. Verbindungen als semaphorininhibitoren
ES2382808T3 (es) * 2003-12-05 2012-06-13 Dainippon Sumitomo Pharma Co., Ltd. Agentes terapéuticos o preventivos para la neuropatía isquémica
US20110092554A1 (en) * 2007-11-19 2011-04-21 Richard Chesworth 1,3,5 tri-subtituted benzenes for treatment of alzheimer's disease and other disorders
US9040062B2 (en) 2010-08-06 2015-05-26 Sumitomo Dainippon Pharma Co., Ltd. Preparation for treatment of spinal cord injury
CA2827869C (en) 2011-02-25 2019-04-02 Dainippon Sumitomo Pharma Co., Ltd. Therapeutic agent for corneal sensory nerve damage containing semaphorin inhibitor as active ingredient
WO2014178427A1 (ja) * 2013-05-02 2014-11-06 学校法人順天堂 セマフォリン３ａの発現調節法
WO2015021226A1 (en) * 2013-08-07 2015-02-12 Board Of Regents, The University Of Texas System Analogs of vinaxanthone and xanthofulvin, methods of synthesis, and methods of treatments thereof
US20170216244A1 (en) * 2014-03-06 2017-08-03 Yale University Methods for treating diabetic nephropathy
CN104945389B (zh) * 2014-03-27 2018-04-13 中国科学院上海药物研究所 一类山酮串色酮类化合物及其制备方法和用途
JP6742343B2 (ja) * 2016-01-15 2020-08-19 大日本住友製薬株式会社 ２環性複素環化合物
US20200056186A1 (en) * 2016-09-22 2020-02-20 Rsem, Limited Partnership Compositions comprising sasp modulators and senescence attenuators and uses thereof for modulating cellular senescence
CN109956952B (zh) * 2017-12-14 2020-11-13 浙江工业大学 α-楝子素衍生物及其制备方法与应用
JP7093489B2 (ja) * 2018-02-27 2022-06-30 学校法人順天堂 脳梗塞に関する治療薬
JP7551502B2 (ja) * 2018-12-12 2024-09-17 住友ファーマ株式会社 新規投与方法
CN113174082B (zh) * 2021-03-30 2022-12-02 中国人民解放军空军军医大学 仿生硅化胶原材料的制备方法及其应用
CN113512018B (zh) * 2021-07-07 2023-07-18 合肥工业大学 一种黄酮类化合物及其制备方法和用途
CN117427063A (zh) * 2023-10-27 2024-01-23 济南大学 吲哚二萜类化合物及其制备方法和在制备神经保护剂中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0580609A1 (de) 1991-03-22 1994-02-02 Xenova Limited Pharmazeutische xanthonderivate
US5229123A (en) * 1991-10-09 1993-07-20 Hoffmann-La Roche Inc. Antifungal agents
US5639856A (en) * 1993-09-13 1997-06-17 The Regents Of The University Of California Semaphorin gene family
US5416197A (en) * 1993-10-15 1995-05-16 Trustees Of The University Of Pennsylvania Antibodies which bind human collapsin
US5674242A (en) 1995-06-06 1997-10-07 Quanam Medical Corporation Endoprosthetic device with therapeutic compound
WO1998011216A1 (en) 1996-09-11 1998-03-19 Sumitomo Pharmaceuticals Company, Limited Novel semaphorin gene: semaphorin y
EP0945505A4 (de) 1996-10-09 2002-11-27 Sumitomo Pharma Neues semaphorin-gen: semaphorin w
EP1135488A1 (de) * 1998-11-26 2001-09-26 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Menschliches semaphorin 6a-1 (sema6a-1), ein gen das beteiligt ist an die neuronal-entwicklung und regenerationsmechanismen während apoptosis, und dessen anwendung als potentielles arzneimittel-ziel

Also Published As

Publication number Publication date
US20030166711A1 (en) 2003-09-04
DE60130769D1 (de) 2007-11-15
EP1306093B1 (de) 2007-10-03
EP1306093A4 (de) 2004-06-30
AU2001276694A1 (en) 2002-02-13
US20070015820A1 (en) 2007-01-18
US7317038B2 (en) 2008-01-08
WO2002009756A1 (en) 2002-02-07
US7244761B2 (en) 2007-07-17
JPWO2002009756A1 (ja) 2004-01-08
EP1306093A1 (de) 2003-05-02
DE60130769T2 (de) 2008-07-17
JP4975231B2 (ja) 2012-07-11
ES2294014T3 (es) 2008-04-01

Similar Documents

Publication Publication Date Title
ATE374623T1 (de) Förderer der nervenregeneration die als aktiven bestandteil einen semaphorinhemmer enthalten
ATE282958T1 (de) Beeinflussung der wirkung von pflanzenwachstumsregulatoren
BR0312695A (pt) Derivados de 1h-pirrolidina-2,4-diona espirocìclicos substituìdos por cis-alcóxi
EP1501507A4 (de) Tetrahydropyranyl-cyclopentyl-tetrahydropyridopyridin-modulatoren der chemokin-rezeptor-aktivität
DE69526790D1 (de) Verbindungen zur hemmung von phosphodiesrerase iv
CO5611065A2 (es) Difluorometiltiazolilcarboxanilidas
ATE311184T1 (de) 1-benzyl-3-(substituiertes-hetaryl)-kondensiert n pyrazol-derivaten zur behandlung von erkrankungen des herz-kreislaufsystems und des zentralnervensystems
RU97106285A (ru) Способ приготовления солода
DE50306845D1 (de) Disubstituierte thiazolylcarboxanilide und ihre verwendung als mikrobizide
RU95105981A (ru) Таксан, способ получения, фармацевтическая композиция
RU95101838A (ru) Промежуточный продукт для получения производных стероидов, способ получения
WO1994020062A3 (en) Balanoids as protein kinase c inhibitors
DE60041055D1 (de) Kombinierte verwendung von mittelkettige fettsäuren enthaltenden triglyceriden und exogenen lipolytischen enzymen als tierfutterzusatzstoffe
WO2003057820A3 (en) Peptide activators of vegf
MX9403286A (es) Acido valerico substituido.
PL374666A1 (en) Pyrrolidine derivatives as oxytocin antagonists
ES2127875T3 (es) Bencenosulfonil-ureas y -tioureas sustituidas con amino, procedimiento para su preparacion y su utilizacion como productos farmaceuticos.
DE69922016D1 (de) R-metalaxyl enthaltende fungizide zusammensetzungen
ATE404216T1 (de) Verstärker der hm1.24 antigen-expression
DE50303586D1 (de) Methylthiophencarboxanilide
AU5857899A (en) Use of tgf-beta inhibitors for treating cerebral disorders
DE60119336D1 (de) Verwendungen von thaliporphin oder seinen derivaten in der behandlung von herzkrankheiten und seine herstellung
BR9905930A (pt) Composição, e, processo para controlar fungos fitopatogênicos em uma planta
WO2024159007A3 (en) 4-hydroxy-n-isopropyltryptamine
WO2001070682A3 (en) Carbocyclic side chain containing metalloprotease inhibitors

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties